Projects

scientist
RNDr. Peter Bališ, PhD.

International

Finished
  • Study the role of iron oxide nanoparticles in a model of hypertension and comorbid Alzheimer\'s disease
    Program: Inter-academic agreement
    Duration: 1. 1. 2018 – 31. 12. 2020
  • Stress-induced pressor responses: endothelial factors vs. central regulation of sympathetic tone
    Program: Inter-academic agreement
    Duration: 1. 1. 2016 – 31. 12. 2017
  • Study of interactions between reactive oxygen species and nitric oxide in search for novel mechanisms of hypertension
    Program: Bilateral - other
    Duration: 1. 1. 2011 – 31. 12. 2013

National

Current
  • Identification of stress-induced alterations in expression of NRF2 target genes in rat models of prehypertension: the effect of comorbid hypertriglyceridemia and dimethyl fumarate treatment
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • Cardiovascular protection mediated by alpha 1 AMPK against metabolic syndrome-mediated endothelial dysfunction - identifying new risk factors
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • New aspects of cardioprotection by natural antioxidants: role of ageing and lifestyle-related comorbidities
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • Hyperuricemia in various comorbidities of the metabolic syndrome - mechanisms of the effect of uric acid on endothelial function and erythrocyte deformability.
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Role of nuclear factor NRF2-mediated signalling in iron metabolism regulation during stress
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
Finished
  • New perspectives in the treatment of cardiovascular complications associated with COVID-19
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • Research of magnetic forms of iron in development of cardiovascular diseases and behavioural disorders
    Program: SRDA
    Duration: 1. 7. 2017 – 30. 6. 2021
  • Mechanisms involved in uric acid-induced endothelial dysfunction depending on the age and genetic predisposition to hypertension
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Effect of ultrasmall superparamagnetic iron oxide nanoparticles on the cardiovascular system of rats with high blood pressure
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Study of regulation of radical and cellular signaling during hypertension and influence of novel therapies on this signaling.
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Effect of aging on the endothelial function in experimental hypertension
    Program: Other projects
    Duration: 17. 4. 2014 – 17. 4. 2017
  • Epicatechin in prevention of early development of primary hypertension: mechanisms of action in the cardiovascular and central nervous systems
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
  • Effect of PPAR gamma agonists on antioxidant response and on regulation of radical and cell signaling in hypertension
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
  • Gender differences in etiopathogenesis of social stress-related cardiovascular and behavioral disorders in individuals with predisposition to hypertension
    Program: SRDA
    Duration: 1. 5. 2011 – 30. 10. 2014
  • Social stress as a risk factor of early development of hypertension in predisposed individuals
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2013
Employees